Use of angiotensin receptor blockers and risk of dementia in a predominantly male population

Prospective cohort analysis

Nien Chen Li, Austin Lee, Rachel Whitmer, Miia Kivipelto, Elizabeth Lawler, Lewis E. Kazis, Benjamin Wolozin

Research output: Contribution to journalArticle

308 Citations (Scopus)

Abstract

Objective: To investigate whether angiotensin receptor blockers protect against Alzheimer's disease and dementia or reduce the progression of both diseases. Design: Prospective cohort analysis. Setting: Administrative database of the US Veteran Affairs, 2002-6. Population: 819 491 predominantly male participants (98%) aged 65 or more with cardiovascular disease. Main outcome measures: Time to incident Alzheimer's disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the "cardiovascular comparator") over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease. Disease progression was the time to admission to a nursing home or death among participants with pre-existing Alzheimer's disease or dementia. Results: Hazard rates for incident dementia in the angiotensin receptor blocker group were 0.76 (95% confidence interval 0.69 to 0.84) compared with the cardiovascular comparator and 0.81 (0.73 to 0.90) compared with the lisinopril group. Compared with the cardiovascular comparator, angiotensin receptor blockers in patients with pre-existing Alzheimer's disease were associated with a significantly lower risk of admission to a nursing home (0.51, 0.36 to 0.72) and death (0.83, 0.71 to 0.97). Angiotensin receptor blockers exhibited a dose-response as well as additive effects in combination with angiotensin converting enzyme inhibitors. This combination compared with angiotensin converting enzyme inhibitors alone was associated with a reduced risk of incident dementia (0.54, 0.51 to 0.57) and admission to a nursing home (0.33, 0.22 to 0.49). Minor differences were shown in mean systolic and diastolic blood pressures between the groups. Similar results were observed for Alzheimer's disease. Conclusions: Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer's disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population.

Original languageEnglish (US)
Article numberb5465
Number of pages1
JournalBMJ (Online)
Volume340
Issue number7738
DOIs
StatePublished - Jan 16 2010
Externally publishedYes

Fingerprint

Angiotensin Receptor Antagonists
Dementia
Alzheimer Disease
Cohort Studies
Population
Nursing Homes
Angiotensin-Converting Enzyme Inhibitors
Lisinopril
Cardiovascular Agents
Preexisting Condition Coverage
Disease Progression
Cardiovascular Diseases
Blood Pressure
United States Department of Veterans Affairs
Proportional Hazards Models
Stroke
Outcome Assessment (Health Care)
Databases
Confidence Intervals

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use of angiotensin receptor blockers and risk of dementia in a predominantly male population : Prospective cohort analysis. / Li, Nien Chen; Lee, Austin; Whitmer, Rachel; Kivipelto, Miia; Lawler, Elizabeth; Kazis, Lewis E.; Wolozin, Benjamin.

In: BMJ (Online), Vol. 340, No. 7738, b5465, 16.01.2010.

Research output: Contribution to journalArticle

Li, Nien Chen ; Lee, Austin ; Whitmer, Rachel ; Kivipelto, Miia ; Lawler, Elizabeth ; Kazis, Lewis E. ; Wolozin, Benjamin. / Use of angiotensin receptor blockers and risk of dementia in a predominantly male population : Prospective cohort analysis. In: BMJ (Online). 2010 ; Vol. 340, No. 7738.
@article{8e8ffa5586214261b2a5aff894a2bca0,
title = "Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis",
abstract = "Objective: To investigate whether angiotensin receptor blockers protect against Alzheimer's disease and dementia or reduce the progression of both diseases. Design: Prospective cohort analysis. Setting: Administrative database of the US Veteran Affairs, 2002-6. Population: 819 491 predominantly male participants (98{\%}) aged 65 or more with cardiovascular disease. Main outcome measures: Time to incident Alzheimer's disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the {"}cardiovascular comparator{"}) over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease. Disease progression was the time to admission to a nursing home or death among participants with pre-existing Alzheimer's disease or dementia. Results: Hazard rates for incident dementia in the angiotensin receptor blocker group were 0.76 (95{\%} confidence interval 0.69 to 0.84) compared with the cardiovascular comparator and 0.81 (0.73 to 0.90) compared with the lisinopril group. Compared with the cardiovascular comparator, angiotensin receptor blockers in patients with pre-existing Alzheimer's disease were associated with a significantly lower risk of admission to a nursing home (0.51, 0.36 to 0.72) and death (0.83, 0.71 to 0.97). Angiotensin receptor blockers exhibited a dose-response as well as additive effects in combination with angiotensin converting enzyme inhibitors. This combination compared with angiotensin converting enzyme inhibitors alone was associated with a reduced risk of incident dementia (0.54, 0.51 to 0.57) and admission to a nursing home (0.33, 0.22 to 0.49). Minor differences were shown in mean systolic and diastolic blood pressures between the groups. Similar results were observed for Alzheimer's disease. Conclusions: Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer's disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population.",
author = "Li, {Nien Chen} and Austin Lee and Rachel Whitmer and Miia Kivipelto and Elizabeth Lawler and Kazis, {Lewis E.} and Benjamin Wolozin",
year = "2010",
month = "1",
day = "16",
doi = "10.1136/bmj.b5465",
language = "English (US)",
volume = "340",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "7738",

}

TY - JOUR

T1 - Use of angiotensin receptor blockers and risk of dementia in a predominantly male population

T2 - Prospective cohort analysis

AU - Li, Nien Chen

AU - Lee, Austin

AU - Whitmer, Rachel

AU - Kivipelto, Miia

AU - Lawler, Elizabeth

AU - Kazis, Lewis E.

AU - Wolozin, Benjamin

PY - 2010/1/16

Y1 - 2010/1/16

N2 - Objective: To investigate whether angiotensin receptor blockers protect against Alzheimer's disease and dementia or reduce the progression of both diseases. Design: Prospective cohort analysis. Setting: Administrative database of the US Veteran Affairs, 2002-6. Population: 819 491 predominantly male participants (98%) aged 65 or more with cardiovascular disease. Main outcome measures: Time to incident Alzheimer's disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the "cardiovascular comparator") over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease. Disease progression was the time to admission to a nursing home or death among participants with pre-existing Alzheimer's disease or dementia. Results: Hazard rates for incident dementia in the angiotensin receptor blocker group were 0.76 (95% confidence interval 0.69 to 0.84) compared with the cardiovascular comparator and 0.81 (0.73 to 0.90) compared with the lisinopril group. Compared with the cardiovascular comparator, angiotensin receptor blockers in patients with pre-existing Alzheimer's disease were associated with a significantly lower risk of admission to a nursing home (0.51, 0.36 to 0.72) and death (0.83, 0.71 to 0.97). Angiotensin receptor blockers exhibited a dose-response as well as additive effects in combination with angiotensin converting enzyme inhibitors. This combination compared with angiotensin converting enzyme inhibitors alone was associated with a reduced risk of incident dementia (0.54, 0.51 to 0.57) and admission to a nursing home (0.33, 0.22 to 0.49). Minor differences were shown in mean systolic and diastolic blood pressures between the groups. Similar results were observed for Alzheimer's disease. Conclusions: Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer's disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population.

AB - Objective: To investigate whether angiotensin receptor blockers protect against Alzheimer's disease and dementia or reduce the progression of both diseases. Design: Prospective cohort analysis. Setting: Administrative database of the US Veteran Affairs, 2002-6. Population: 819 491 predominantly male participants (98%) aged 65 or more with cardiovascular disease. Main outcome measures: Time to incident Alzheimer's disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the "cardiovascular comparator") over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease. Disease progression was the time to admission to a nursing home or death among participants with pre-existing Alzheimer's disease or dementia. Results: Hazard rates for incident dementia in the angiotensin receptor blocker group were 0.76 (95% confidence interval 0.69 to 0.84) compared with the cardiovascular comparator and 0.81 (0.73 to 0.90) compared with the lisinopril group. Compared with the cardiovascular comparator, angiotensin receptor blockers in patients with pre-existing Alzheimer's disease were associated with a significantly lower risk of admission to a nursing home (0.51, 0.36 to 0.72) and death (0.83, 0.71 to 0.97). Angiotensin receptor blockers exhibited a dose-response as well as additive effects in combination with angiotensin converting enzyme inhibitors. This combination compared with angiotensin converting enzyme inhibitors alone was associated with a reduced risk of incident dementia (0.54, 0.51 to 0.57) and admission to a nursing home (0.33, 0.22 to 0.49). Minor differences were shown in mean systolic and diastolic blood pressures between the groups. Similar results were observed for Alzheimer's disease. Conclusions: Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer's disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population.

UR - http://www.scopus.com/inward/record.url?scp=74949131237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949131237&partnerID=8YFLogxK

U2 - 10.1136/bmj.b5465

DO - 10.1136/bmj.b5465

M3 - Article

VL - 340

JO - The BMJ

JF - The BMJ

SN - 0959-8146

IS - 7738

M1 - b5465

ER -